Botulinum toxin for hereditary spastic paraplegia: effects on motor and non-motor manifestations

• Main Author: Servelhere,Katiane R.
• Publication Date: 2018
• Other Authors: Faber,Ingrid, Martinez,Alberto, Nickel,Renato, Moro,Adriana, Germiniani,Francisco M. B., Moscovich,Mariana, Blume,Tatiane R., Munhoz,Renato P., Teive,Hélio A. G., França Jr,Marcondes C.
• Format: Article
• Language: eng
• Source: Arquivos de neuro-psiquiatria (Online)
• Download full: http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0004-282X2018000300183
• topic: botulinum toxin; spastic paraplegia; hereditary; muscle spasticity

ABSTRACT Motor and non-motor manifestations are common and disabling features of hereditary spastic paraplegia (HSP). Botulinum toxin type A (Btx-A) is considered effective for spasticity and may improve gait in these patients. Little is known about the effects of Btx-A on non-motor symptoms in HSP patients. Objective To assess the efficacy of Btx-A on motor and non-motor manifestations in HSP patients. Methods Thirty-three adult patients with a clinical and molecular diagnosis of HSP were evaluated before and after Btx-A injections. Results Mean age was 41.7 ± 13.6 years and there were 18 women. Most patients had a pure phenotype and SPG4 was the most frequent genotype. The Btx-A injections resulted in a decrease in spasticity at the adductor muscles, and no other motor measure was significantly modified. In contrast, fatigue scores were significantly reduced after Btx-A injections. Conclusion Btx-A injections resulted in no significant functional motor improvement for HSP, but fatigue improved after treatment.